Use of pathological response versus RECIST assessment in predicting relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.

Authors: Antonio D'Alessio, Pasquale Lombardi, Bernardo Stefanini, Julia Blanter, Fionnuala Crowley, Daniel Shu, Vincent Yip, Sarah Slater, Madhava Pai, Robert D. Goldin, Stephen Ward, M. Isabel Fiel, Yung-Yeh Su, Marina Baretti, Robert A. Anders, Mark Yarchoan, Chiun Hsu, Thomas Urban Marron, Rohini Sharma, David James Pinato,

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.633

Source: Full article

---

Abstract

633